NCT00607243View on ClinicalTrials.gov

Safety and Efficacy of CJ-50300 in Healthy Volunteers

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2008

Conditions

Smallpox

Interventions

BIOLOGICAL

smallpox vaccine CJ-50300

Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

HK inno.N Corporation

All Listed Sponsors

collaborator

HK inno.N Corporation

INDUSTRY

lead

Seoul National University Hospital

OTHER